Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 07:32pm CET

Talcum Powder Lawsuit Plaintiffs Claim Unsealed Documents Show Johnson & Johnson Knew of Talc- Asbestos Danger in 1970s, Bernstein Liebhard LLP Reports

By a News Reporter-Staff News Editor at Women's Health Weekly -- Plaintiffs pursuing talcum powder lawsuits in Missouri state court claim that newly unsealed documents show that Johnson & Johnson has known since the 1970s that its talc-based powders contained asbestos fibers, which could increase the risk of ovarian cancer in women who used the products for daily feminine hygiene. (Case No. 1522-CC10417, Circuit Court, City of St. Louis, Missouri)

"Our Firm is representing women who allegedly developed ovarian cancer due to Johnson & Johnson's talcum powder products. These documents are of great interest to our clients, and we will continue to monitor the Missouri litigation for any other developments that could impact their claims," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to women who were diagnosed with ovarian cancer that may be associated with Johnson & Johnson'sBaby Powder and Shower-to-Shower products (see also Bernstein Liebhard Llp).

Keywords for this news article include: Talc, Asbestos, Oncology, Gynecology, Legal Issues, Silicic Acid, Women's Health, Silicon Dioxide, Silicon Compounds, Inorganic Chemicals, Magnesium Silicates, Risk and Prevention, Mixed Ovarian Cancer, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
12:46p Sanofi investors hungry for drug progress and deal news
12:09a JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
12/11 JOHNSON & JOHNSON : Sustained Benefit in Patients With Relapsed/Refractory Mantl..
12/11 JOHNSON & JOHNSON : How Johnson & Johnson is Helping Support Service Members Thr..
12/11 JOHNSON & JOHNSON : Wetherby Asset Management Holds Holding in Johnson & Johnson..
12/09 JOHNSON & JOHNSON : Sustained Benefit in Patients with Relapsed/Refractory Mantl..
12/09 JOHNSON & JOHNSON : Investigational Mosaic HIV-1 Preventive Vaccine Enters its F..
12/09 JOHNSON & JOHNSON : Janssen Romania invested EUR 154,000 in first cancer palliat..
12/08 Edgewell touts creation of 140 new jobs at Dover plant
12/08 JOHNSON & JOHNSON : Woman suing j&j testifies she's in pain
More news
News from SeekingAlpha
12/11 Johnson & Johnson files U.S. marketing application for expanded label use of ..
12/11 Where To Invest To Benefit From The Corporate Tax Cut
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/10 WEEK IN REVIEW : China Life Science Deals Total $550 Million
12/08 Esketamine Could Give Johnson & Johnson The Next Major Psych Blockbuster
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,37%
P/E ratio 2017 23,66
P/E ratio 2018 19,47
EV / Sales 2017 5,19x
EV / Sales 2018 4,79x
Capitalization 379 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 3,2%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN18.98%128 363